Lebrikizumab延长治疗对16周未达方案缓解标准的中重度特应性皮炎患者的疗效
本文分析了两项随机对照试验中,接受lebrikizumab每2周诱导治疗16周未达方案定义缓解标准(EASI 75或IGA 0/1且改善≥2分且未用抢救药物)的患者,后续接受开放标签lebrikizumab治疗至52周的疗效。结果显示,16周时38.1%的患者因未达标准进入逃逸臂,但其中多数已获EASI≥50%改善(58.1%);至52周,36.1%达IGA 0/1且改善≥2分,75.5%达EASI 75,44.2%达EASI 90,66.4%报告瘙痒NRS改善≥4分。结论提示延长治疗可使这部分患者获益。
要点
- 16周未达方案缓解标准者中多数已获EASI≥50%改善。
- 延长lebrikizumab治疗至52周可使部分患者达EASI 75等终点。
- 临床对16周应答不佳者不宜过早停药,可考虑延长治疗。
核心结论
- 接受lebrikizumab治疗16周未达方案定义缓解标准的患者,继续延长治疗至52周仍可获益。
研究设计与样本
- 基于ADvocate1和ADvocate2两项随机对照临床试验的观察数据分析。
- 纳入诱导期每2周接受lebrikizumab治疗16周未达方案缓解标准、随后接受开放标签lebrikizumab治疗的患者。
主要发现
- 16周时38.1%的lebrikizumab治疗患者因未达缓解标准进入逃逸臂。
- 这些患者中58.1%在16周时已达EASI≥50%改善。
- 52周时36.1%达IGA 0/1且改善≥2分,75.5%达EASI 75,44.2%达EASI 90,66.4%报告瘙痒NRS改善≥4分。
关键数值与推荐
- 方案定义缓解标准为EASI 75或IGA 0/1且改善≥2分且未用抢救药物。
- 52周疗效数值:IGA 0/1且改善≥2分36.1%,EASI 75 75.5%,EASI 90 44.2%,瘙痒NRS改善≥4分66.4%。
临床怎么用
- 对16周未达方案缓解标准但已有部分改善的患者,可考虑继续lebrikizumab治疗至52周以评估长期获益。
局限性
- 分析为开放标签治疗,允许合并外用治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lebrikizumab demonstrated statistically significant improvements in patients with moderate-to-severe atopic dermatitis at week 16 with a durable response up to week 52. OBJECTIVE: To investigate the efficacy of lebrikizumab-treated patients at 52 weeks who did not achieve the ADvocate1 and ADvocate2 protocol-defined response criteria (≥75% improvement in the Eczema Area and Severity Index [EASI 75] or Investigator Global Assessment 0/1 with ≥2-point improvement without rescue medication) after 16 weeks. METHODS: This analysis includes observed data for patients who received lebrikizumab every 2 weeks during the induction period, did not achieve the protocol-defined response, and subsequently received open-label lebrikizumab treatment. RESULTS: At week 16, 38.1% of lebrikizumab-treated patients entered the escape arm due to not achieving the response criteria. However, most of these patients had achieved ≥50% improvement in EASI (58.1%) by week 16. At week 52, 36.1% achieved Investigator Global Assessment 0/1 with ≥2-point improvement, 75.5% achieved EASI 75, 44.2% achieved ≥90% improvement in EASI, and 66.4% reported ≥4-point Pruritus Numeric Rating Scale improvement. LIMITATIONS: This analysis assesses patients receiving open-label treatment with concomitant topical therapy allowed. CONCLUSION: Lebrikizumab-treated patients not achieving the protocol-defined response at week 16 can benefit from the continuation of longer-term therapy.
引用
- Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, et al. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol. 2024. PMID: 39733939. doi:10.1016/j.jaad.2024.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。